tert-butyl (9-oxo-9H-fluoren-2-yl)carbamate | 387392-90-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: tert-butyl (9-oxo-9H-fluoren-2-yl)carbamate
• 英文别名: tert-butyl N-(9-oxofluoren-2-yl)carbamate
• CAS: 387392-90-7
• 化学式: C₁₈H₁₇NO₃
• 分子量: 295.338
• InChiKey: HKKNRMKYIHFBEH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl (9-oxo-9H-fluoren-2-yl)carbamate 在 sodium tetrahydroborate 、 氯化亚砜 、 N,N-二甲基甲酰胺 作用下， 以 甲醇 、 乙醚 为溶剂， 生成 tert-butyl (9-chloro-9H-fluoren-2-yl)carbamate
  参考文献：
  名称：

  DBU 介导的二聚化：轻松获得 9,9'-二芴基和异靛蓝

  摘要：

  目前的工作描述了 1,8-二氮杂双环[5.4.0]十一碳-7-烯 (DBU) 促进的 9-氯芴和 3-氯羟吲哚的自二聚反应，用于制备相应的 9,9'-二芴基和异靛蓝衍生品的收益率为 29-97%。该反应在温和且无金属的条件下在短反应时间内容易地进行。选定的 9,9'-亚二芴衍生物的放大合成（5.0 mmol）以良好的产率进行，突出了所报告方案的合成效用。

  DOI：

  10.1055/a-2158-7980
• 作为产物：
  描述：

  2-氨基芴 在 叔丁基过氧化氢 、 sodium carbonate 、 potassium iodide 作用下， 以 1,4-二氧六环 、 水 、 乙腈 为溶剂， 反应 6.0h， 生成 tert-butyl (9-oxo-9H-fluoren-2-yl)carbamate
  参考文献：
  名称：

  DBU 介导的二聚化：轻松获得 9,9'-二芴基和异靛蓝

  摘要：

  目前的工作描述了 1,8-二氮杂双环[5.4.0]十一碳-7-烯 (DBU) 促进的 9-氯芴和 3-氯羟吲哚的自二聚反应，用于制备相应的 9,9'-二芴基和异靛蓝衍生品的收益率为 29-97%。该反应在温和且无金属的条件下在短反应时间内容易地进行。选定的 9,9'-亚二芴衍生物的放大合成（5.0 mmol）以良好的产率进行，突出了所报告方案的合成效用。

  DOI：

  10.1055/a-2158-7980

文献信息

• [EN] COMPOSITIONS AND METHODS OF MAKING EXPANDED HEMATOPOIETIC STEM CELLS USING DERIVATIVES OF FLUORENE<br/>[FR] COMPOSITIONS ET PROCÉDÉS DE PRODUCTION DE CELLULES SOUCHES HÉMATOPOÏÉTIQUES EXPANSÉES METTANT EN OEUVRE DES DÉRIVÉS DE FLUORÈNE
  申请人：TRANSFUSION HEALTH LLC

  公开号：WO2019084452A1

  公开（公告）日：2019-05-02

  This invention is directed to, inter alia, compounds, methods, systems, and compositions for the maintenance, enhancement, and expansion of hematopoietic stem cells derived from one or more sources of CD34+ cells. Sources of CD34+ cells include bone marrow, cord blood, mobilized peripheral blood, and non-mobilized peripheral blood. Also provided herein are compounds of Formula I which are useful in maintaining, enhancing, and expanding of hematopoietic stem cells.

  这项发明涉及一些内容，包括用于维持、增强和扩展来源于一个或多个CD34+细胞源的造血干细胞的化合物、方法、系统和组合物。CD34+细胞的来源包括骨髓、脐带血、动员的外周血和非动员的外周血。本文还提供了一些Formula I的化合物，这些化合物在维持、增强和扩展造血干细胞方面是有用的。
• METHODS OF MAKING OLIGOPOTENT AND UNIPOTENT PRECURSORS
  申请人：Transfusion Health, LLC

  公开号：US20220315895A1

  公开（公告）日：2022-10-06

  This disclosure is directed to, inter alia, methods and systems for preparing oligopotent and unipotent progenitor cells of defined lineages in culture from an expanded source of CD34+ cells, media for making the same, and therapeutic compounds and compositions comprising the same for treatment a variety of diseases included, but not limited to, hematologic disorders, immune diseases, cancers, and infectious diseases.

  本公开涉及的是从扩增的CD34+细胞来源中在培养中准备定义谱系的寡能和单能祖细胞的方法和系统，用于制备相应的培养基，以及包含相应的治疗化合物和组合物，用于治疗各种疾病，包括但不限于血液学疾病、免疫性疾病、癌症和传染性疾病。
• Structure–activity relationships and optimisation of the selective MDR modulator 2-(3,4-dimethoxyphenyl)-5-(9-fluorenylamino)-2-(methylethyl) pentanenitrile and its N-methyl derivative
  作者：Silvia Dei、Elisabetta Teodori、Arlette Garnier-Suillerot、Fulvio Gualtieri、Serena Scapecchi、Roberta Budriesi、Alberto Chiarini

  DOI：10.1016/s0968-0896(01)00191-2

  日期：2001.10

  Several ring-substituted derivatives of previously studied MDR inhibitors 2-(3,4-dimethoxyphenyl)-5-(9-fluorenylamino)-2-(methylethyl)pentanenitrile and 2-(3,4-dimethoxyphenyl)-5-[(9-fluorenyl)-N-methylamino]-2-(methylethyl)pentanenitrile have been synthesised and Studied with the aim of optimising activity and selectivity. The results show that MDR inhibition is scarcely sensitive to modulation of the electronic properties of the fluorene ring. Even if dramatic improvement was not obtained, one of the compounds (2) showed improved potency and selectivity with respect to the leads and appears to be a better candidate for drug development. (C) 2001 Elsevier Science Ltd. All rights reserved.
• COMPOSITIONS AND METHODS OF MAKING EXPANDED HEMATOPOIETIC STEM CELLS USING DERIVATIVES OF FLUORENE
  申请人：Transfusion Health, LLC

  公开号：US20200255371A1

  公开（公告）日：2020-08-13

  This invention is directed to, inter alia, compounds, methods, systems, and compositions for the maintenance, enhancement, and expansion of hematopoietic stem cells derived from one or more sources of CD34+ cells. Sources of CD34+ cells include bone marrow, cord blood, mobilized peripheral blood, and non-mobilized peripheral blood. Also provided herein are compounds of Formula I which are useful in maintaining, enhancing, and expanding of hematopoietic stem cells.
• [EN] METHODS OF MAKING OLIGOPOTENT AND UNIPOTENT PRECURSORS<br/>[FR] PROCÉDÉS DE FABRICATION DE PRÉCURSEURS OLIGOPOTENTS ET UNIPOTENTS
  申请人：TRANSFUSION HEALTH LLC

  公开号：WO2020223517A1

  公开（公告）日：2020-11-05

  This disclosure is directed to, inter alia, methods and systems for preparing oligopotent and unipotent progenitor cells of defined lineages in culture from an expanded source of CD34+ cells, media for making the same, and therapeutic compounds and compositions comprising the same for treatment a variety of diseases included, but not limited to, hematologic disorders, immune diseases, cancers, and infectious diseases.